李昀 | 撰文高翼 | 编辑近日,阿斯利康宣布退出CNS(中枢神经系统)类药物的开发,引发业界热议。4月29日,公司在投资者电话会议上宣布了这一消息。同时发布的2025年一季度财报显示,公司已经终止了多项相关管线,包括与礼来合作开发治疗阿尔茨海默症的MEDI1814、处于2期临床的偏头痛单抗MEDI0618、治疗糖尿病神经痛的双抗MEDI7352,至此公司神经科学在研管线全部清零。对这一结果,业内...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.